MicroPort NeuroTech Limited (MicroPort NeuroTech™), as a member of Microport Scientific Corporation (00853.HK, MicroPort), has been researching and developing industry leading neuro-interventional medical devices since 2002. We are dedicated to providing universal stroke treatment solutions to patients and physicians worldwide. Since the approval of our first product - APOLLO™ intracranial stent system in 2004, we have been developing a comprehensive product portfolio which covers three major neurovascular disease areas, specifically Hemorrhagic Stroke, Intra and Extracranial Atherosclerotic Stenosis, and Acute Ischemic Stroke. We currently have 12 approved products used in more than 1998 hospitals worldwide, supporting 134 surgeries on average every day, and have been awarded 109 domestic and foreign authorized patents to date. Headquartered in Shanghai Zhangjiang Science City, NeuroTech employs over 400 people worldwide. In our pursuit of excellence, we aspire to improve the lives of patients, physicians and our employees, and to create innovative solutions for neurovascular stroke disorders. Together, our efforts will continue to impact the health and well-being of people globally. For more information, please visit https://www.medneurotech.com/en/indexen